KALA BIO, Inc.

LSE:0JQ2 Stock Report

Market Cap: US$27.7m

KALA BIO Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0JQ2?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders180,3123.91%
VC/PE Firms443,6619.62%
Institutions777,78916.9%
Hedge Funds1,172,78125.4%
General Public2,035,59644.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 71.2%.

Top Shareholders

Top 25 shareholders own 55.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.3%
Baker Bros. Advisors LP
891,335US$5.3m0%0.05%
9.62%
SR One Capital Management, LP
443,661US$2.7m0%0.59%
6.1%
ADAR1 Capital Management, LLC
281,446US$1.7m-8.04%0.32%
3.65%
Lagunita Biosciences
168,454US$1.0m0%no data
3.53%
UBS O'Connor LLC
162,663US$976.0k10.2%0.09%
3.05%
Millennium Management LLC
140,731US$844.4k-1.09%no data
2.35%
Longitude Capital Management Co., LLC
108,239US$649.4k0%0.13%
1.57%
Mark Iwicki
72,451US$434.7k0%no data
1.16%
The Vanguard Group, Inc.
53,570US$321.4k6.53%no data
0.81%
Geode Capital Management, LLC
37,116US$222.7k96.5%no data
0.54%
R. Brazzell
24,689US$148.1k0%no data
0.53%
Spearhead Insurance Solutions Idf, Llc
24,621US$147.7k0%7.69%
0.49%
Todd Bazemore
22,385US$134.3k0%no data
0.48%
Darius Kharabi
22,154US$132.9k0%no data
0.47%
Renaissance Technologies LLC
21,473US$128.8k0%no data
0.46%
BlackRock, Inc.
21,356US$128.1k0%no data
0.46%
Stanford Management Company
21,127US$126.8k0%0.01%
0.35%
Mary Reumuth
16,056US$96.3k0%no data
0.3%
Two Sigma Investments, LP
14,005US$84.0k0%no data
0.17%
Mark Blumenkranz
7,752US$46.5k0%no data
0.085%
Eric Trachtenberg
3,917US$23.5k0%no data
0.066%
Andrew Koven
3,058US$18.3k0%no data
0.065%
Howard Rosen
3,012US$18.1k0%no data
0.051%
Gregory Perry
2,369US$14.2k0%no data
0.029%
Charles Myers
1,321US$7.9k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:24
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

KALA BIO, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Yi ChenH.C. Wainwright & Co.
Raghuram SelvarajuH.C. Wainwright & Co.